The Award database is continually updated throughout the year. As a result, data for FY19 is not expected to be complete until September, 2020.
SBC: VASCULAR BIOSCIENCES, INC. Topic: NHLBI
PUBLIC ABSTRACT This projectin response to announcement HLSdescribes a development program for CARSKNKDCCARa synthetic cyclic peptide that selectively targets diseased pulmonary vascular endothelium and enhances the therapeutic effect of vasodilator therapiesfor the treatment of pulmonary hypertensionPHPH is a disorder of elevated pulmonary vascular resistance characterized by progressive thickeni ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Leukogene Therapeutics Inc. Topic: 102
Project Summary Abstract Multiple MyelomaMMis the second most common form of blood cancer and remains an incurable and deadly diseaseProteasome inhibitorPItherapy is a cornerstone in the treatment of MMbut resistance to this class of agent is an emerging challenge in the clinicNew therapeutic approaches that specifically target resistance are needed to maximize responses and ultimately produce cur ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health
SBC: Eppin Pharma Inc Topic: NICHD
The global contraceptives market was valued at $billion inand is expected to grow at a CAGR offromtoto reach an estimated value of $billion inThe contraceptive market consists of short term methods such as condoms and oral contraceptionlong term methods including implants and IUDsand permanent methods such as tubal ligations and vasectomiesEppin Pharmaandapos s product has a unique set of characte ...STTR Phase II 2018 Department of Health and Human ServicesNational Institutes of Health